Treatment of Major Depressive Disorder
For moderate to severe major depressive disorder, initiate treatment with either cognitive behavioral therapy (CBT) alone OR a second-generation antidepressant alone as monotherapy—both options provide similar benefits with moderate-certainty evidence. 1, 2
First-Line Treatment Selection
The choice between CBT and antidepressants should be driven by:
- Adverse event profile: Second-generation antidepressants carry higher discontinuation rates due to adverse events compared to psychotherapy, with over 60% of patients experiencing at least one side effect 3
- Patient-specific symptoms: Consider insomnia, hypersomnia, or appetite fluctuations when selecting treatment
- Feasibility and access: CBT requires availability of trained therapists and patient time commitment
- Cost considerations: Evaluate insurance coverage and out-of-pocket expenses
- Patient preference: This is paramount in shared decision-making 2
For Mild Depression
Start with CBT monotherapy rather than antidepressants (conditional recommendation, low-certainty evidence) 2. Psychological interventions are appropriate first-line for less severe presentations 4.
Combination Therapy Option
Combination therapy (CBT plus second-generation antidepressant) may be considered for moderate to severe MDD, though this is a conditional recommendation based on low-certainty evidence 2. Interestingly, recent 2026 meta-analysis data suggests adding antidepressants to psychotherapy may not provide additional benefit (SMD = 0.31; CI 95% [-0.07; 0.70], p=0.1), though this evidence is rated as very low quality 5.
Second-Generation Antidepressants
These include:
- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- Other agents targeting neurotransmitters selectively 3
Critical caveat: Up to 70% of patients do not achieve remission with initial antidepressant treatment 3, necessitating a clear second-step strategy.
Second-Step Treatment for Inadequate Response
When a patient fails to respond to an adequate dose of a second-generation antidepressant, you have equivalent options:
Option 1: Add or Switch to CBT
- Augment the current antidepressant with CBT, OR
- Switch entirely to CBT 2
Option 2: Medication Strategy
- Switch to a different second-generation antidepressant, OR
- Augment with a second pharmacologic agent 2
All switching and augmentation strategies provide similar symptomatic relief based on network meta-analysis, though certainty of evidence remains low for most comparisons 3.
Long-Term Relapse Prevention
The sequential integration of CBT after acute-phase pharmacotherapy response significantly reduces relapse risk (risk ratio: 0.781; 95% CI=0.671-0.909; number needed to treat=8) 6.
Specifically:
- Adding CBT during antidepressant continuation reduces relapse compared to antidepressants alone (NNT=10) 6
- Most compelling: Patients who receive CBT and then taper antidepressants have lower relapse rates than those continuing medication alone (risk ratio: 0.674; NNT=5) 6
This sequential model—pharmacotherapy in acute phase followed by psychotherapy in residual phase—represents a highly effective strategy for preventing recurrence 6.
Important Clinical Pitfalls
- Don't assume combination therapy is always superior: The evidence for combining treatments initially is weaker than for monotherapy 5, 2
- Don't continue ineffective treatment: With 70% non-remission rates, have a clear second-step plan ready 3
- Don't overlook lifestyle interventions: Stress management, sleep hygiene, and healthy lifestyle changes should be implemented alongside or before formal treatments 7, 4
- Don't ignore treatment history: The 2024 update confirms these recommendations remain current despite new studies 1
Evidence Quality Context
Most treatment comparisons carry low-certainty evidence due to methodological limitations, dosing inequalities, and potential publication bias 3. The 2024 ACP guideline surveillance found no conclusion-changing evidence requiring updates 1. Focus on options with the most reliable evidence and prioritize patient preferences given the similar efficacy across treatments 3.